JY231 cell therapy for relapsed B-cell lymphoma or leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 75 years old.
- Your cancer has the CD19 marker (tested on a sample of your blood or bone marrow).
- You have a B-cell lymphoma or B-ALL that has come back or not responded to standard treatment.
- You have at least one treatable tumor (≥1.5 cm) or ≥5% cancer cells in bone marrow.
- Your organs (kidneys, liver, heart, lungs) are working well enough to handle treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called JY231 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy targets a protein called CD19 on cancer cells, helping your immune system attack them.
This trial tests a new injectable treatment (called JY231) for people whose B-cell lymphoma has come back or did not respond to standard treatments. The treatment targets a specific marker on cancer cells (CD19) and may help when other options have not worked.
This trial tests a new drug, YK012, for people with a certain kind of B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not gotten better after standard therapies. It aims to see if the drug is safe and works against these leukemia cells that have the CD19 marker.
This trial tests an investigational CAR-T cell therapy called JY232 for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy targets a protein called BCMA on myeloma cells to help your immune system fight the cancer.
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
Hear when a new B-Non Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.